Somnus Therapeutics Inc, Bedminster, NJ, has unveiled its scientific advisory board (SAB), a panel of international sleep researchers and clinicians.
“Research on normal sleep rhythms and circadian disorders has improved medical understanding of the effects of shift-work, jet-lag, and night light exposure on sleep,” says Gary Cupit, chief executive officer of Somnus. “Such research highlights the continuing need for improved medicines to help those who suffer disrupted circadian sleep-wake cycles. Therefore, we have assembled an advisory board of distinguished scientists and clinicians with experience treating sleep-disordered patients and conducting insomnia drug clinical trials.”
The complete list of scientific advisory board members can be found on the Somnus Therapeutics Web site.